PEGylated Factor VIII Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A require frequent infusions of Factor VIII due to its short half-life, leading to a heavy burden on patients and difficulties in venous access, with limited understanding of the clearance mechanism and receptor interactions hindering the development of agents to extend Factor VIII half-life.
Innovation Solution
Modifying Factor VIII or Von Willebrand Factor with water-soluble polymers such as PEG, PEO, or polysialic acid to reduce binding affinity with clearance receptors like LRP1, thereby inhibiting interaction and extending the protein's half-life in circulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Factor VIII is administered frequently to maintain therapeutic levels, then hemostatic efficacy is improved, but patient burden and venous access difficulty increase
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of Factor VIII by conjugating it with polyethylene glycol (PEG) chains of varying molecular weights. This chemical modification changes the physical-chemical properties of Factor VIII, specifically increasing its hydrodynamic radius and reducing its recognition by clearance receptors, thereby extending its half-life from 10-30 hours to potentially 50-100 hours or longer, which reduces infusion frequency
Solution Approach 2:
The invention creates a composite molecular structure by covalently attaching PEG polymers to Factor VIII, forming a Factor VIII-PEG conjugate. This composite structure combines the hemostatic functionality of Factor VIII with the extended circulation properties of PEG, achieving both therapeutic efficacy and prolonged duration of action
2Duration of action of moving object
If Factor VIII half-life is extended by interfering with clearance mechanisms, then infusion frequency is reduced, but knowledge of clearance receptors and molecular sites is required
Solution Approach 1:
The patent uses PEG polymers as intermediary molecules that physically block the interaction between Factor VIII and clearance receptors without requiring detailed knowledge of the specific receptor-binding interfaces. The PEG chains act as steric barriers that prevent receptor recognition, effectively interfering with the clearance mechanism at a distance from the actual binding sites
Solution Approach 2:
The invention replaces the need for precise molecular understanding of clearance mechanisms with a steric hindrance approach. Instead of designing molecules that specifically avoid known receptor binding sites (which would require detailed structural knowledge), the patent uses bulky PEG chains to create a physical barrier that mechanically prevents receptor access through size exclusion
3Duration of action of moving object
If PEGylation is used to extend Factor VIII half-life, then clearance is reduced, but molecular weight and viscosity may increase
Solution Approach 1:
The patent employs dynamic PEG chains with flexible linkers that allow the conjugate to adopt different conformations in solution. The PEG chains can dynamically collapse or extend depending on solvent conditions, allowing the molecule to maintain a compact effective size while still providing sufficient steric protection against clearance, thus balancing half-life extension with acceptable hydrodynamic volume
Data Source
AI summary
The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.